AR133035A1 - Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr) - Google Patents
Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr)Info
- Publication number
- AR133035A1 AR133035A1 ARP240101597A ARP240101597A AR133035A1 AR 133035 A1 AR133035 A1 AR 133035A1 AR P240101597 A ARP240101597 A AR P240101597A AR P240101597 A ARP240101597 A AR P240101597A AR 133035 A1 AR133035 A1 AR 133035A1
- Authority
- AR
- Argentina
- Prior art keywords
- hmgcr
- dsrna
- antisense strand
- strand
- expression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan composiciones y métodos útiles para reducir la expresión del gen de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR) y para el tratamiento de enfermedades y afecciones asociadas a HMGCR. Se proporcionan agentes de ARNbc de HMGCR, agentes polinucleotídicos antisentido de HMGCR, composiciones que comprenden agentes de ARNbc de HMGCR y composiciones que comprenden agentes polinucleotídicos antisentido de HMGCR que pueden usarse para reducir la expresión de HMGCR en células y sujetos. Reivindicación 1: Un agente de ácido ribonucleico bicatenario (ARNbc) para inhibir la expresión de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR), en donde el agente de ARNbc que incluye una cadena sentido y una cadena antisentido, en donde la cadena sentido comprende al menos 15 nucleótidos contiguos que difieren en no más de 3 nucleótidos de la secuencia de nucleótidos de la SEQ ID Nº 1 y la cadena antisentido comprende al menos 15 nucleótidos contiguos que difieren en no más de 3 nucleótidos de la secuencia de nucleótidos de la SEQ ID Nº 2, en donde la cadena sentido y la cadena antisentido pueden ser parcial, sustancial o totalmente complementarias entre sí. Reivindicación 4: Un agente de ácido ribonucleico bicatenario (ARNbc) para inhibir la expresión de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR), en donde el agente de ARNbc comprende una cadena sentido y una cadena antisentido, comprendiendo las posiciones de nucleótidos 2 a 18 en la cadena antisentido una región de complementariedad a un transcrito de ARN de HMGCR, en donde la región de complementariedad comprende al menos 15 nucleótidos contiguos que difieren en 0, 1, 2 o 3 nucleótidos de una de las secuencias antisentido enumeradas en una de las Tablas 1 - 3, y comprendiendo opcionalmente un ligando de direccionamiento. Reivindicación 6: Un agente de ácido ribonucleico bicatenario (ARNbc) para inhibir la expresión de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR), en donde el agente de ARNbc incluye una cadena sentido y una cadena antisentido, en donde la cadena antisentido de ARNbc es sustancialmente o totalmente complementaria a una cualquiera de una región diana de la SEQ ID Nº 1, y preferentemente el agente de ARNbc comprende una secuencia de cadena antisentido expuesta en una cualquiera de las Tablas 1 - 3. Reivindicación 11: Un agente de ácido ribonucleico bicatenario (ARNbc) para inhibir la expresión de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR), en donde el agente de ARNbc incluye una cadena sentido y una cadena antisentido, en donde la cadena sentido es complementaria a la cadena antisentido, en donde la cadena antisentido comprende una región complementaria a parte de un ARNm que codifica HMGCR, en donde cada cadena tiene de aproximadamente 15 a aproximadamente 30 nucleótidos de longitud, en donde la secuencia de cadena sentido puede representarse por la fórmula (1): 5-(NL)ₙ NLNL NN₁ NN₂ NN₃ NN₄ NL NF NL NN₅ NN₆ NL NL NL (NL)ₘ-3 (1) en donde: cada NF representa un nucleótido modificado con 2-fluoro; cada NN₁, NN₂, NN₃, NN₄, NN₅ y NN₆ representa independientemente un nucleótido modificado o sin modificar; cada NL representa independientemente un nucleótido modificado o sin modificar, pero no un nucleótido modificado con 2-fluoro; y m y n son cada uno independientemente un número entero de 0 a 7. Reivindicación 39: Una composición que comprende un agente de ARNbc de una cualquiera de las reivindicaciones 1 - 38. Reivindicación 44: Una célula que comprende un agente de ARNbc de una cualquiera de las reivindicaciones 1 - 38, opcionalmente, la célula es una célula de mamífero, opcionalmente una célula humana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023101548 | 2023-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133035A1 true AR133035A1 (es) | 2025-08-20 |
Family
ID=93934852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101597A AR133035A1 (es) | 2023-06-21 | 2024-06-21 | Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr) |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR133035A1 (es) |
| TW (1) | TW202500747A (es) |
| UY (1) | UY40801A (es) |
| WO (1) | WO2024260434A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| US20040006031A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of HMG-CoA reductase expression |
| FR2840217B1 (fr) * | 2002-06-03 | 2005-06-24 | Oreal | Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations |
| EP3604537B1 (en) * | 2003-06-13 | 2021-12-08 | Alnylam Europe AG | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| MX2007007283A (es) * | 2007-06-15 | 2009-02-18 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal. |
| WO2023009687A1 (en) * | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
-
2024
- 2024-06-21 AR ARP240101597A patent/AR133035A1/es unknown
- 2024-06-21 UY UY0001040801A patent/UY40801A/es unknown
- 2024-06-21 TW TW113123012A patent/TW202500747A/zh unknown
- 2024-06-21 WO PCT/CN2024/100524 patent/WO2024260434A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY40801A (es) | 2024-12-13 |
| WO2024260434A1 (en) | 2024-12-26 |
| TW202500747A (zh) | 2025-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU778474B2 (en) | Method and medicament for inhibiting the expression of a defined gene | |
| WO2000063364A3 (en) | Methods and compositions for inhibiting the function of polynucleotide sequences | |
| WO2006073601A3 (en) | Methods and compositions for rna interference | |
| WO2005089287A3 (en) | Methods and compositions for the specific inhibition of gene expression by double-stranded rna | |
| BR112022014513A2 (pt) | Agentes caotrópicos para reduzir a formação de rna de fita dupla | |
| RU2011124146A (ru) | Композиции и способы подавления экспрессии генов фактора vii | |
| AR123420A1 (es) | Inhibidores de dux4 y métodos de uso de estos | |
| US10612020B2 (en) | Artificial mimic miRNA for controlling gene expression, and use of same | |
| JP2022078058A (ja) | ゲノム編集方法 | |
| Brinkman et al. | Nucleoside analogs in ADAR guide strands targeting 5′-UA [combining low line] sites | |
| MX2025010451A (es) | Composiciones y métodos para la inhibición de la expresión de genes de la subunidad beta e de la inhibina (inhbe) | |
| Yu et al. | Comprehensive analysis of miRNA profiles reveals the role of Schistosoma japonicum miRNAs at different developmental stages | |
| AR133035A1 (es) | Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr) | |
| Wang et al. | Testis brain ribonucleic acid-binding protein/translin possesses both single-stranded and double-stranded ribonuclease activities | |
| MX2025006656A (es) | Oligonucleotidos antisentido para el tratamiento de enfermedades cardiovasculares | |
| WO2021202443A3 (en) | Compositions and methods for silencing dnajc15 gene expression | |
| Kang et al. | Optimization of double‐stranded RNAi intrathoracic injection method in Aedes aegypti | |
| WO2024211376A3 (en) | Compositions and methods for treating cag repeat diseases | |
| AR131145A1 (es) | Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria | |
| US20140066595A1 (en) | Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom | |
| KR101181728B1 (ko) | 세포 내 rpS3 발현 억제 siRNA | |
| KR20210120034A (ko) | 사람 세포내 부착 분자 1(icam-1)에 대한 안티센스 약물 | |
| CN102965371A (zh) | 一种抑制BMP15基因表达的siRNA 及其应用 | |
| Priyadarshini et al. | Downregulation of ribosomal RNA (rRNA) genes in human head and neck squamous cell carcinoma (HNSCC) cells is linked to rDNA promoter hypermethylation | |
| AR126265A1 (es) | Composiciones y métodos para silenciar la expresión de myoc |